Clinical trial
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated…
NCT00070499 · National Cancer Institute (NCI), NIH · Active, not recruiting
Key facts
| NCT number | NCT00070499 |
|---|---|
| Title | Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia |
| Official title | A Phase IIb Study of Molecular Responses to Imatinib, at Standard or Increased Doses, or Dasatinib (BMS-354825) (NSC-732517) for Previously Untreated Patients With Chronic Myelogenous Leukemia (CML) in Chronic Phase |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia, BCR-ABL1 Positive |
| Intervention type | Drug, Other |
| Interventions | Dasatinib, Imatinib Mesylate, Laboratory Biomarker Analysis |
| Enrollment | 406 |
| Start date | Aug 15, 2004 |
| Primary completion | Nov 1, 2010 |
| Completion | Mar 10, 2026 |
| First posted | Oct 7, 2003 |
| Last update posted | Aug 21, 2025 |
| Countries | Canada, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: